Management of Decompensated Cirrhotic Liver Disease

Immediate Assessment and Referral

The American Association for the Study of Liver Diseases recommends that all patients with decompensated cirrhosis and portal hypertension should be referred to a hepatologist for comprehensive evaluation and management of complications 2, 3
Screen for clinically significant portal hypertension using hepatic venous pressure gradient (HVPG) ≥10 mmHg, or non-invasively with liver stiffness measurement (LSM) by transient elastography combined with platelet count, as recommended by the European Association for the Study of the Liver 2, 3

The American Association for the Study of Liver Diseases recommends removing the underlying cause of liver disease, which is associated with decreased risk of further decompensation and increased survival 1
Eliminate alcohol consumption completely in alcohol-related cirrhosis, as recommended by the American College of Gastroenterology 1

The American College of Gastroenterology recommends non-selective beta-blockers (NSBBs) as the cornerstone of portal hypertension management, reducing portal pressure by decreasing cardiac output and causing splanchnic vasoconstriction 5, 4
Carvedilol 12.5 mg/day is superior to traditional NSBBs due to additional alpha-1 receptor blockade, achieving hemodynamic response in 50-75% of patients, as recommended by the European Association for the Study of the Liver 4

The American College of Gastroenterology recommends endoscopic band ligation (EBL) as an alternative to NSBBs if contraindicated, though NSBBs are preferred as they prevent other portal hypertension complications 5
Initiate vasoactive drugs (octreotide or terlipressin) immediately when variceal hemorrhage is suspected, before endoscopy, as recommended by the International Society for the Study of Portal Hypertension 4

The International Society for the Study of Portal Hypertension strongly recommends TIPS for gastroesophageal variceal bleeding refractory to endoscopic and drug therapy 5
Early or pre-emptive TIPS should be considered within 72 hours of variceal bleed in high-risk patients, as recommended by the European Association for the Study of the Liver 5

The American Association for the Study of Liver Diseases recommends that patients with decompensated cirrhosis should be evaluated for liver transplantation, which offers the only effective therapeutic option for end-stage liver disease 2, 3
Indications for transplant evaluation include acute or chronic liver failure, recurrent/refractory ascites, refractory variceal bleeding, and hepatocellular carcinoma (HCC) within transplant criteria, as recommended by the United Network for Organ Sharing 2, 3

The European Association for the Study of the Liver recommends HVPG measurement to guide therapy when available, with target reduction to ≤12 mmHg or ≥20% reduction from baseline 5
Doppler ultrasound to assess portal system patency after interventions, as recommended by the Society of Interventional Radiology 5